---
layout: post
title: "A Risk-Based Approach to Monitoring of Clinical Investigations-Questions and Answers; Guidance for Industry; Correction"
date: 2026-02-05 18:55:24 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-09264
original_published: 2023-05-02 00:00:00 +0000
significance: 8.00
---

# A Risk-Based Approach to Monitoring of Clinical Investigations-Questions and Answers; Guidance for Industry; Correction

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** May 02, 2023 00:00 UTC
**Document Number:** 2023-09264

## Summary

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 12, 2023. The document announced the availability of a final guidance entitled "A Risk-Based Approach to Monitoring of Clinical Investigations--Questions and Answers; Guidance for Industry." The notice of availability for this final guidance was published with an incorrect OMB control number. This document corrects that error.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/05/02/2023-09264/a-risk-based-approach-to-monitoring-of-clinical-investigations-questions-and-answers-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2023-09264

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
